How Cagrilintide (AM833) Works: Unique Pharmacology Across Amylin and Calcitonin Receptors
Cagrilintide (AM833) has a unique pharmacological profile as a nonselective agonist of both amylin and calcitonin receptors, distinguishing it from pramlintide and other peptide agonists across 25 different measures.
Quick Facts
What This Study Found
AM833 (cagrilintide) is a nonselective agonist with a unique pharmacological profile across 25 endpoints of receptor binding, activation, and regulation compared to 5 other selective and nonselective AMYR/CTR agonists including pramlintide and salmon calcitonin.
Key Numbers
25 endpoints; 7 peptides compared; AM833 nonselective at AMYR + CTR; unique profile vs pramlintide (selective), salmon CT (nonselective), and 4 others
How They Did This
In vitro pharmacological profiling. AM833 compared against AM1213, AM1784, pramlintide, salmon calcitonin, human calcitonin, and rat amylin across 25 endpoints measuring receptor binding, signaling activation, and receptor regulation at calcitonin and amylin receptor subtypes.
Why This Research Matters
Understanding why cagrilintide works better than selective agonists helps optimize next-generation obesity drugs. The nonselective receptor profile explains its additive effects when combined with GLP-1 drugs like semaglutide (CagriSema).
The Bigger Picture
Cagrilintide represents the evolution from pramlintide (a selective amylin receptor agonist with modest effects) to a nonselective dual-receptor agonist with substantially greater weight loss potential. Understanding this pharmacology guides the design of future obesity peptide drugs.
What This Study Doesn't Tell Us
In vitro receptor pharmacology study — does not directly measure weight loss or clinical outcomes. Receptor-level activity may not fully predict in vivo efficacy. Differences between cell-based assays and physiological conditions are possible.
Questions This Raises
- ?Does the dual CTR/AMYR activation explain cagrilintide's additive effects with semaglutide?
- ?Could the receptor regulation profile predict which patients respond best to cagrilintide?
- ?Can the pharmacological insights from this study guide design of even more effective amylin analogues?
Trust & Context
- Key Stat:
- 25 endpoints profiled Cagrilintide showed a distinct pharmacological fingerprint across 25 measures of receptor binding, activation, and regulation versus 5 other peptide agonists
- Evidence Grade:
- Moderate evidence: comprehensive in vitro pharmacological characterization supporting clinical findings, but receptor-level data does not directly predict therapeutic outcomes.
- Study Age:
- Published 2021. Cagrilintide has since advanced to Phase 3 clinical trials in combination with semaglutide (CagriSema) for obesity.
- Original Title:
- AM833 Is a Novel Agonist of Calcitonin Family G Protein-Coupled Receptors: Pharmacological Comparison with Six Selective and Nonselective Agonists.
- Published In:
- The Journal of pharmacology and experimental therapeutics, 377(3), 417-440 (2021)
- Authors:
- Fletcher, Madeleine M, Keov, Peter, Truong, Tin T, Mennen, Grace, Hick, Caroline A, Zhao, Peishen, Furness, Sebastian G B, Kruse, Thomas, Clausen, Trine R, Wootten, Denise, Sexton, Patrick M
- Database ID:
- RPEP-05383
Evidence Hierarchy
Frequently Asked Questions
What makes cagrilintide different from pramlintide?
Pramlintide only activates amylin receptors, while cagrilintide activates both amylin and calcitonin receptors. This broader receptor activation appears to produce greater weight loss effects. Cagrilintide also has a longer half-life allowing once-weekly dosing.
Why does activating multiple receptors matter for weight loss?
Amylin and calcitonin receptors control different aspects of appetite and metabolism. Activating both simultaneously may produce additive satiety signals, and when combined with GLP-1 drugs (which target yet another receptor), the combination could achieve weight loss approaching surgical levels.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05383APA
Fletcher, Madeleine M; Keov, Peter; Truong, Tin T; Mennen, Grace; Hick, Caroline A; Zhao, Peishen; Furness, Sebastian G B; Kruse, Thomas; Clausen, Trine R; Wootten, Denise; Sexton, Patrick M. (2021). AM833 Is a Novel Agonist of Calcitonin Family G Protein-Coupled Receptors: Pharmacological Comparison with Six Selective and Nonselective Agonists.. The Journal of pharmacology and experimental therapeutics, 377(3), 417-440. https://doi.org/10.1124/jpet.121.000567
MLA
Fletcher, Madeleine M, et al. "AM833 Is a Novel Agonist of Calcitonin Family G Protein-Coupled Receptors: Pharmacological Comparison with Six Selective and Nonselective Agonists.." The Journal of pharmacology and experimental therapeutics, 2021. https://doi.org/10.1124/jpet.121.000567
RethinkPeptides
RethinkPeptides Research Database. "AM833 Is a Novel Agonist of Calcitonin Family G Protein-Coup..." RPEP-05383. Retrieved from https://rethinkpeptides.com/research/fletcher-2021-am833-is-a-novel
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.